-
Data From Landmark Clinical Trial of Abbott's MitraClip® System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment
Monday, April 4, 2011 - 9:05am | 125Abbott (NYSE: ABT) today announced data from its EVEREST II study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClip® system continue to demonstrate the clinical benefits of initial treatment shown at one...
-
Forest Laboratories Announces Amendment to Merger Agreement and Extends Tender Offer to Acquire Clinical Data, Inc.
Monday, April 4, 2011 - 8:54am | 110Forest Laboratories (NYSE: FRX) today announced that its indirect wholly-owned subsidiary, Magnolia Acquisition Corp, has extended the expiration date of its tender offer for all outstanding shares of common stock of, and certain outstanding notes and warrants convertible into the common stock of,...
-
CryoLife Files Investigational Device Exemption to Begin Clinical Trials for PerClot in the U.S.
Monday, April 4, 2011 - 8:35am | 65CryoLife, Inc. (NYSE: CRY) announced today that it has filed an IDE with the United States Food and Drug Administration (FDA) to begin clinical trials for the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot in the U.S. to control bleeding during surgical procedures or following...
-
Piper Jaffray Maintains Underweight Rating On KCI
Monday, April 4, 2011 - 8:32am | 132Piper Jaffray has issued a report reiterating an Underweight Rating on Kinetic Concepts (NYSE: KCI). According to the report, "Tomorrow's meeting at CMS regarding Competitive Bidding, Round 2 in our view has three potential outcomes worth noting, two of which could potentially drive volatility for...
-
St. Jude Medical Receives FDA Approval for New Bi-Directional Ablation Catheters
Monday, April 4, 2011 - 8:31am | 93St. Jude Medical, Inc. (NYSE: STJ) announced today that it has received U.S. Food and Drug Administration (FDA) approval of two new irrigated ablation catheters - the Safire BLU™ Bi-directional Irrigated Ablation Catheter and the Therapy™ Cool Path™ bi-directional ablation catheter. These two new...
-
Wedbush Raises PT On Edwards Lifesciences To $75
Monday, April 4, 2011 - 8:30am | 27Wedbush Securities has raised the price target on Edwards Lifesciences (NYSE: EW) from $68 to $75 and maintains its Underperform rating.
-
Jefferies Upgrades Edwards Lifesciences To Buy
Monday, April 4, 2011 - 8:15am | 79According to Jefferies, Edwards Lifesciences (NYSE: EW) is upgraded to Buy. Jefferies reported that, following the release of PARTNER Cohort A results and Cohort B economic benefit analysis, it is upgrading EW shares to Buy from Hold. “Based on the strong data and very positive clinician feedback...
-
UPDATE: Morgan Keegan Raising Price Target On Baxter (BAX)
Monday, April 4, 2011 - 7:53am | 171Morgan Keegan is raising its price target on shares of Baxter International Inc. (NYSE: BAX) to $62 from $60, and it has a Buy rating on shares. In a note to clients, Morgan Keegan writes, "Data from the Plasma Proteins Therapeutics Association (PPTA), which was released on March 24, suggested...
-
Wunderlich Has Buy Rating On ABIOMED (ABMD)
Monday, April 4, 2011 - 7:32am | 166Wunderlich Securities has a Buy rating and a $18 price target on shares of ABIOMED, Inc. (NASDAQ: ABMD). In a note to clients, Wunderlich writes, "The full Protect II trial data was presented Sunday at the American College of Cardiology (ACC) meeting. As we have suggested, the greater use of...
-
Piper Jaffray Reports On Edward Lifesciences' Clinical Trials
Monday, April 4, 2011 - 7:31am | 118Piper Jaffray has issued a report on Edward Lifesciences' (NYSE: EW) latest clinical trials. According to the report, "At 12-month follow-up, high risk surgical patients implanted with the Sapien valve reported an all cause mortality rate of 24.2% compared to 26.8% (p=0.001 for non-inferiority)....
-
Citi Comments On Edwards Lifesciences' One-Year Results
Monday, April 4, 2011 - 7:21am | 121According to Citi, Edwards Lifesciences (NYSE: EW) presented the one-year results of the high-risk Cohort A of its randomized PARTNER trial for the SAPIEN transcatheter valve at the ACC 2011 conference in New Orleans on Sunday. Citi reported that major stroke rates were higher than SAVR but lower...
-
Oppenheimer Reports Another Pipeline Add And Checks At ACC On Medtronic
Monday, April 4, 2011 - 7:18am | 136According to Oppenheimer, Medtronic (NYSE: MDT) continued to add to its list of near-term pipeline launches with late Friday's FDA approval of InterStim TherapyBowel Control. Oppenheimer reported that the fecal incontinence indication has been a solid driver of InterStim sales in the EU. “The US...
-
Deutsche Bank Maintains Hold On Edwards Lifesciences
Monday, April 4, 2011 - 7:12am | 214According to Deutsche Bank, Edwards Lifesciences (NYSE: EW) rating is maintained at Hold. Deutsche Bank reported that Cohort A met its primary endpoint of non-inferiority to surgical valve replacement. “However, at the current valuation we believed this was already fully priced in. There was a...
-
http://www.benzinga.com/node/add/storyPiper Jaffray Reports On ABMD's PROTECT II
Monday, April 4, 2011 - 7:10am | 123Piper Jaffray has issue a report on the positive clinical trial results from Abiomed's (NASDAQ: ABMD) PROTECT II study. According to the report, "While the trial did not achieve its primary endpoint, there were multiple aspects of it that were encouraging. In particular, in the cohort of patients...
-
Citigroup Raises PT On Edwards Lifesciences To $99
Monday, April 4, 2011 - 6:44am | 27Citigroup has raised the price target on Edwards Lifesciences Corporation (NYSE: EW) from $79 to $99 and maintains its Buy rating.